• Issue

    Hematological Oncology: Volume 42, Issue 2

    March 2024
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • First Published: 27 January 2024

ORIGINAL ARTICLE

Open Access

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study

Thierry Facon,  Philippe Moreau,  Ivan Špicka,  Kenshi Suzuki,  Kwee Yong,  Joseph Mikhael,  Taro Fukao,  Kamlesh Bisht,  Nicole M. Armstrong,  Sandrine Macé,  Marie-Laure Risse,  Thomas Martin, 
  • First Published: 25 February 2024

Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis

Rong Wang,  Yi Zhang,  Jie Chang,  Huafeng Wang,  Yinjun Lou,  Min Yang,  Gaixiang Xu,  Hongyan Tong,  Wanzhuo Xie,  De Zhou,  Juying Wei,  Wenyuan Mai,  Xiujin Ye,  Haitao Meng,  Jie Jin,  Hong-Hu Zhu, 
  • First Published: 28 February 2024

LETTER TO THE EDITOR

Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?

Andrea Duminuco,  Antonella Nardo,  Giuseppe A. Palumbo, 
  • First Published: 25 February 2024

ORIGINAL ARTICLE

Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement

Elisabetta M. Abenavoli,  Flavia Linguanti,  Matilde Anichini,  Vittorio Miele,  Francesco Mungai,  Marianna Palazzo,  Luca Nassi,  Benedetta Puccini,  Ilaria Romano,  Benedetta Sordi,  Roberto Sciagrà,  Gabriele Simontacchi,  Alessandro M. Vannucchi,  Valentina Berti, 
  • First Published: 07 March 2024

LETTER TO THE EDITOR

Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy

Enrico Grande,  Francesco Grippo,  Claudio Barbiellini Amidei,  Ugo Fedeli,  Alberto Tosetto, 
  • First Published: 29 February 2024

New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model

Maria Anele Romeo,  Chiara Focaccetti,  Andrea Arena,  Rossella Benedetti,  Michele Di Crosta,  Camilla Palumbo,  Maria Saveria Gilardini Montani,  Roberta Santarelli,  Roberta Gonnella,  Gabriella D’Orazi,  Roberto Bei,  Mara Cirone, 
  • First Published: 07 March 2024

ORIGINAL ARTICLE

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia

Yuan Sun,  Xu Wang,  Wen-Min Chen,  Yue Hao,  Ling-Di Li,  Jin-Ying Li,  Kai Sun,  Zong-Yan Shi,  Hao Jiang,  Qian Jiang,  Xiao-Jun Huang,  Ya-Zhen Qin, 
  • First Published: 10 March 2024

The role of baseline 2-[18F]-FDG-PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

Domenico Albano,  Anna Calabrò,  Francesco Dondi,  Samuele Bagnasco,  Alessandra Tucci,  Francesco Bertagna, 
  • First Published: 05 March 2024

REVIEW

Open Access

How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

Nayla Mouawad,  Edoardo Ruggeri,  Guido Capasso,  Leonardo Martinello,  Andrea Visentin,  Federica Frezzato,  Livio Trentin, 
  • First Published: 08 February 2024

LETTER TO THE EDITOR

Treatment-related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase-based regimens: A multicenter electronic health research network study

Benjamin J. Lee,  Shawn P. Griffin, 
  • First Published: 07 February 2024

ORIGINAL ARTICLE

Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia

Marijana Virijevic,  Nada Kraguljac-Kurtovic,  Mirjana Mitrovic,  Ljubomir Jakovic,  Zoran Bukumuric,  Nikola Pantic,  Nikica Sabljic,  Zlatko Pravdic,  Mirjana Cvetkovic,  Vesna Knezevic,  Tijana Dragovic-Ivancevic,  Irena Djunić,  Jovan Rajic,  Violeta Milosevic,  Milena Todorovic-Balint,  Ana Vidovic,  Nada Suvajdzic-Vukovic, 
  • First Published: 27 January 2024

REVIEW

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel

Francesca Romana Mauro,  Alessandra Tedeschi,  Marzia Varettoni,  Francesco Zaja,  Giovanni Barosi,  Pier Luigi Zinzani, 
  • First Published: 16 February 2024

ORIGINAL ARTICLE

Open Access

Antibody targeting of surface P-selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition

João L. Pereira,  Francisca Ferreira,  Nuno R. dos Santos, 
  • First Published: 28 February 2024

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis

Lin-Ya Wang,  Yao Li,  Qian Jiang,  Hao Jiang,  Yu Wang,  Lan-Ping Xu,  Xiao-Hui Zhang,  Kai-Yan Liu,  Fei-Fei Tang, 
  • First Published: 17 February 2024